Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Авдеев С.Н. Современные возможности небулайзерной терапии: принципы работы и новые технические решения // РМЖ «Медицинское обозрение». – 2013. – № 19. – С. 945–952.
  2. Бердников Р.Б., Гринберг Л.М., Евсеев А.Ю., Камаев Е.Ю., Кравченко М.А. Летальный случай генерализованного микобактериоза у больного с терминальной стадией ВИЧ-инфекции // Туберкулез и болезни легких. – Том 94. – № 4. – 2016. – С. 57–62.
  3. Вейсфеллер Д. Биология и изменчивость микобактерий туберкулеза и атипичные микобактерии: экспериментальные и теоретические исследования. Изд-во АН Венгрии, Будапешт. – 1975. – 335 с.
  4. Гунтупова Л.Д., Борисов С.Е., Гришина Т.П., Кузьмин Д.Е., Зюзя Ю.Р. Случай микобактериоза органов дыхания, вызванный M. kansasii // Инфекционные болезни: новости мнения обучение. – 2016. - № 2 (15). – С. 65–72.
  5. Гунтупова Л.Д., Борисов С.Е., Древаль П.А., Воробьев А.А., Исаева Ю.Д. Микобактериозы легких: хирургические аспекты диагностики и лечения // Туберкулез и болезни легких. – 2016. - № 5. – С. 18–26.
  6. Гунтупова Л.Д., Борисов С.Е., Макарова М.В., Хачатурьянц Е.Н. Микобактериозы органов дыхания: эпидемиология, микробиологические и клинические аспекты диагностики // Эпидемиология и инфекционные болезни. – 2012. – № 2. – С. 8–14.
  7. Гунтупова Л.Д., Борисов С.Е., Соловьева И.П., Гармаш Ю.Ю., Матвеева М.В. Клинико-морфологическая характеристика микобактериозов легких // Архив патологии. – 2011. – №5 (73). – С. 12–16.
  8. Гунтупова Л.Д., Борисов С.Е., Соловьева И.П., Макарова М.В., Хачатурьянц Е.Н. Микобактериозы во фтизиопульмонологической практике: обзор литературы и собственный опыт // Практическая медицина. – 2011. – № 3 (51). – С. 39–50.
  9. Елисеев П.И., Марьяндышев А.О., Тарасова И.В., Хелдал А., Хиндеракер С.Г. Диагностика и лечение легочного микобактериоза у пациентов с подозрением на туберкулез легких // Туберкулез и болезни легких. – Том 96. – № 7. – 2018. – С. 61– 62.
  10. Костинов М.П. Вакцинация взрослых – от стратегии к тактике. Руководство для врачей. – М.: Группа МДВ. – 2020. – 248 с.
  11. Литвинов В.И., Дорожкова И.Р., Макарова М.В., Краснова М.А., Фрейман Г.Е. Выделение и идентификация нетуберкулезных микобактерий // Вестник РАМН. – 2010. – № 3. – С.7–11.
  12. Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии // М.: МНПЦБТ. – 2008. – 255 с.
  13. Майорова А.А. Идентификация нетуберкулезных микобактерий и выбор оптимальной комбинации методов для их видовой дифференциации // Автореф. дисс. … канд. биол. наук. – М. – 2007. – 26 с.
  14. Макарова М.В. Выделение и идентификация нетуберкулезных микобактерий у пациентов фтизиатрических учреждений // Автореф. дисс. … докт. мед. наук. – М. – 2010. – 48 с.
  15. МКБ-10 Международная статистическая классификация болезней. – 2003. – 924 с.
  16. Нетуберкулезные микобактерии, микобактериозы / Под ред. В.И. Литвинова, Е.М. Богородской, С.Е. Борисова. – М.: МНПЦБТ. – 2014. – 256 с.
  17. Определитель бактерий Берджи. – 9-е изд. – В 2 т. – Пер. с англ. / Под редак. Дж. Хоулта, Н.Крига, П.Снита, Дж.Стейли, С.Уилльямса. – М.: Мир. – 1997. – 800 с.
  18. Оттен Т.Ф. Микобактериоз легких: клинико-бактериологические критерии диагностики // БЦЖ о туб. – 1999. – № 3. – С. 17–19.
  19. Оттен Т.Ф., Васильев А.В. Микобактериоз // СПб.: Мед.пресса. – 2005. – 224 с.

  1. Петрова Л.В., Мельникова Е.И., Соловьев Ю.А., Ларионова Е.Е., Севастьянова Э.В. Выявление нетуберкулезных микобактерий в республике Марий Эл // Туберкулез и болезни легких. – 2018. – Том 96. – № 2. – С. 41–46.
  2. Поляков А.Е., Сафронова С.Г., Скотникова О.И. Определение множественной лекарственной устойчивости M. tuberculosis различными методами // Проблемы туберкулеза. – 2006. – № 6. – С. 40–42.
  3. Регистр лекарственных средств России РЛС. Энциклопедия лекарств. – 2021. – 1456 с.
  4. Респираторная медицина: руководство: в 3 т. / Под ред. А.Г. Чучалина. 2-е изд., перераб. и доп. – М.: Литерра. – 2017. – Т. 2. – 544 с.: ил. Раздел 9. 9.7 Микобактериозы.
  5. Руководство по ведению пациентов с латентной туберкулезной инфекцией // ВОЗ. WHO/HTM/TB/2015.01. – 2015. – 40 с.
  6. Соловьева И.П., Батыров Ф.А., Пономарев А.Б., Федоров Д.Н. Патологическая анатомия туберкулеза и дифференциальная диагностика гранулематозных заболеваний (Атлас. Для последипломного обучения специалистов научных, лечебных и учебных медицинских учреждений) // М. – 2005. – 260 с.
  7. Суркова Л.К., Сагальчик Е.Р., Борисенко Т.Д., Залуцкая О.М. Распространенность нетуберкулезных микобактерий, проблемы диагностики и лечения микобактериозов // Вести нац. акад. наук Белоруссии. – 2011. – № 2. – С. 12–18.
  8. Федеральные клинические рекомендации по организации и проведению микробиологической и молекулярно-генетической диагностики туберкулеза // М. – 2014. – 29 с.
  9. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И. Клинические рекомендации Хроническая обструктивная болезнь легких // Москва. – 2018. – 89 с.
  10. Adzic-Vukicevic Т., Barac А., Blanka-Protic А., Laban-Lazovic М., Lukovic В., Skodric- Trifunovic V., Rubino S. Clinical features of infection caused by non-tuberculous mycobacteria: 7 years’ experience // Infection. – 2018. – Vol. 46. – № 3. – Р. 357–363.
  11. Ahn C.H., Ahn S.S., Anderson R.A., Murphy D.T., Mammo A. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex // Am. Rev. Respir. Dis. – 1986. – Vol. 134. – Р. 438–441.
  12. Ahn C.H., Lowell J.R., Ahn S.A., Ahn S., Hurst G.A. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs // Rev. Infect. Dis. – 1981. – Vol. 3. – Р. 1028–1034.
  13. Ahn C.H., Lowell J.R., Ahn S.S., Ahn S.I., Hurst G.A. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii // Am. Rev. Respir. Dis. – 1983. – Vol. 128. – Р. 1048–1050.
  14. Ahn C.H., McLarty I.W., Ahn S.S., Ahn S.I., Hurst G.A. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare // Am. Rev. Respir. Dis. – 1982. – Vol. 125. – Р. 388-391. Abstract.
  15. Ahn C.H., Wallace R.J.Jr., Steele L.C., Murphy D.T. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii // Am. Rev. Respir. Dis. – 1987. – Vol. 135. – P. 10–16.
  16. Akram S.M., Bhimji S.S. Mycobacterium Chelonae // Source StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018.
  17. Andréjak C., Lescure F.X., Douadi Y., Laurans G., Smail A., Duhaut P., Jounieaux V., Schmit J.L. Non-tuberculous mycobacteria pulmonary infection: management and follow- up of 31 infected patients // J. Infect. – 2007. – Vol. 55(1). – Р. 34–40.
  18. Andrejak C., Lescure F.X., Pukenyte E., Douadi Y., Yazdanpanah Y. et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France // Thorax. – 2009. Vol. 64. – Р. 659–665.
  19. Andrejak C., Thomsen V.O., Johansen I.S. et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors // Am. J. Respir. Crit. Care Med. – 2010. – Vol. 181. – P. 514–521.
  20. Axson E.L., Bloom C.I., Quint J.K. Nontuberculous mycobacterial disease managed within UK primary care, 2006-2016 // Eur. J. Clin. Microbiol. Infect. Dis. – 2018. – Vol. 37(9). – Р. 1795–1803.
  21. Babady N.E., Hall L., Abbenyi A.T., Eisberner J.J., Brown-Elliott B.A., Pratt C.J., McGlasson M.C., Beierle K.D., Wohlfiel S.L., Deml S.M., Wallace R.J. Jr, Wengenack N.L. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and JustOne strips // J. Clin. Microbiol. – 2010. – Vol. 48(5). – Р. 1749–1752.
  22. Bakuła Z., Kościuch J., Safianowska A., Proboszcz M., Bielecki J., van Ingen J., Krenke R., Jagielski T. Clinical, radiological and molecular features of Mycobacterium kansasii pulmonary disease // Respir. Med. – 2018. – Vol. 139. – Р. 91–100.
  23. Banks J., Hunter A.M., Campbell I.A., Jenkins P.A., Smith A.P. Pulmonary infection with Mycobacterium xenopi: review of treatment and response // Thorax. – 1984. – Vol. 39. – Р. 376–382.
  24. Basille D., Jounieaux V., Andréjak C. Treatment of Other Nontuberculous Mycobacteria // Semin. Respir. Crit. Care Med. – 2018. – Vol. 39(3). – Р. 377–382.
  25. Billinger M.E., Olivier K.N., Viboud C. et al. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. – Emerg. Infect. Dis. – 2009. – Vol. 15. – P. 1562–1569.
  26. Blanc Р., Dutronc H., Peuchant О., Dauchy F-A., Cazanave С., Neau D., Wirth G., Pellegrin J.-L., Morlat P., Mercié P., Tunon-de-Lara J.-M., Doutre M.-S., Pélissier Р., Dupon M. Nontuberculous Mycobacterial Infections in a French Hospital: A 12-Year Retrospective Study // [PLoS One]. 2016. Dec 13. 11(12): e0168290. Published online 2016.
  27. Bodle E.E., Cunningham J.A., Della-Latta P., Schluger N.W., Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City // Emerg. Infec.t Dis. – 2008. – Vol. 14(3). – Р. 390–396.
  28. Bottcher J., Gangl A. Mycobacterium avium ssp. Paratuberculosis – combined serological testing and classification of individual animals and herds // J. Vet. Med. B. Infect. Dis. Vet. Pfblic Health. – 2004. – Vol. 51. – P. 443 – 448.
  29. Brown B.A., Wallace R.J.Jr., Onyi G.O., De Rosa V., Wallace R.J. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms // Antimicrob. Agents Chemother. – 1992. – Vol. 36. – P. 180–184.
  30. Brown-Elliott B., Wallace R. Infections caused by nontuberculous mycobacteria // Principles and practice of infectious disease / ed. G. Mandell. – 2005. – Vol. 2. – P. 2909– 2916.
  31. Brown-Elliott B.A., Nash K.A., Wallace R.J. Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25(3). – Р. 545–582.
  32. Bryant J.M., Grogono D.M., Greaves D. et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study // Lancet. – 2013. – Vol. 381. – Р. 1551–1560.
  33. Bryant J.M., Grogono D.M., Parkhill J. et al. Transmission of Mycobacterium abscessus in patients with cystic fibrosis – Authors’ reply // Lancet. – 2013. – Vol. 382. – Р. 504.
  34. Bryant J.M., Grogono D.M., Rodriguez-Rincon D. et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium // Science. – 2016. – Vol. 354. – Р. 751–757.
  35. Butler W.C.J., Shutt K. Nontuberculous mycobacteria reported to the Public Health Laboratory Information System by state public health laboratories, United States, 1993– 1996. Centers for Disease Control and Prevention. – 1999.
  36. Carneiro M.D.S., Nunes L.S., David S.M.M., Dias C.F., Barth A.L., Unis G. Nontuberculous mycobacterial lung disease in a high tuberculosis incidence setting in Brazil // J. Bras. Pneumol. – 2018. – Vol. 44(2). – Р. 106–111.
  37. Carrillo M.C., Patsios D., Wagnetz U. et al. Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi // Can. Assoc. Radiol. J. – 2014. – Vol. 65(3). – Р. 207–213.
  38. Carro М.L., Barbero Herranz E., Nieto Royo R. Respiratory infections due to nontuberculous mycobacterias // Med. Clin. (Barc). – 2018. – Vol. 150(5). – Р. 191–197.
  39. Cassidy P.M., Hedberg K., Saulson A. et al. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology // Clin. Infect. Dis. – 2009. – Vol. 49. – P. 124–129.
  40. Cavusoglu C., Gurpinar T., Ecemis T. Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by Sensititre RAPMYCO panel //. New Microbiol. – 2012. – Vol. 35(1). – Р. 73–76.
  41. Centers for Disease Control and Prevention. Mycobacterium chelonae infections associated with facelifts: New Jersey, 2002–2003 // MMWR Morb. Mortal Wkly Rep. – 2004. – Vol. 53. – Р. 192–194.
  42. Chaisson R.E., Benson C.A., Dube M.P., Heifets L.B., Korvick J.A., Elkin S., Smith T., Craft J.C., Sattler F.R. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS // Ann. Intern. Med. 1994. – Vol. 121. – Р. 905 –911.
  43. Chou C.H., Chen H.Y., Chen C.Y., Huang C.T., Lai C.C., Hsueh P.R. Clinical features and outcomes of disseminated infections caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 2004–2008 // Scand. J. Infect. Dis. – 2011. – Vol. 43(1). – Р. 8–14.
  44. Chung J.H., Huitt G., Yagihashi K., Hobbs S.B., Faino A.V., Bolster B.D. Jr., Biederer J., Puderbach M., Lynch D.A. Proton Magnetic Resonance Imaging for Initial Assessment of Isolated Mycobacterium avium Complex Pneumonia // Ann. Am. Thorac. Soc. – 2016. – Vol. 13(1). – Р. 49 – 57.
  45. Clinical and laboratopy standards Institute. Susceptibility Testing of Mycоbacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard-Second Edition M 24 – A2. – CLSI. – 2011.
  46. Cook J.L. Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts // Br. Med. Bull. – 2010. – Vol. 96. – Р. 45–59.
  47. Corpe R.F. Surgical management of pulmonary disease due to Mycobacterium avium- intracellulare // Rev. Infect. Dis. – 1981. – Vol. 3. – Р. 1064–1067.
  48. Cowman S., Burns K., Benson S., Wilson R., Loebinger M.R. The antimicrobial susceptibility of non-tuberculous mycobacteria // J. Infect. – 2016. – Vol. 72(3). – Р. 324- 331.
  49. da Silva Telles M.A., Chimara E., Ferrazoli L., Riley L.W. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates // J. Med. Microbiol. – 2005. – Vol. 54(Pt 10). – Р. 975–979.
  50. Dai J., Chen Y., Lauzardo M. Web-accessible database of hsp65 sequences from Mycobacterium reference strains // J. Clin. Microbiol. – 2011. – Vol. 49(6). – Р. 2296– 2303.
  51. Dailloux M., Abalain M., Laurain C. et al. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients // Eur. Respir. J. – 2006. - Vol. 28. – P. 1211 – 1215.
  52. Daley C.L., Griffith D.E. Pulmonary non-tuberculous mycobacterial infections // Int. J. Tuberc. Lung Dis. – 2010. – Vol. 14 (6). – Р. 665–671.
  53. Dautzenberg B., Piperno D., Diot P., Truffot-Pernot C., Chavin J.P. Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS // Chest. – 1995. – Vol. 107. – Р. 1035–1040.
  54. Dautzenberg B., Saint T., Meyohas M.C. et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome // Arch. Intern. Med. - 1993. – Vol. 153. – P. 368 – 372.
  55. Dautzenberg B., Truffot C., Legris S., et al. Activity of clarithromycin against Mycobacterium avium infection in patients with acquired immune deficiency syndrome // Am. Rev. Respir. Dis. – 1991. – Vol. 144. – P. 564–569.
  56. Davidson P.T., Khanijo V., Gable M., Moulding T.S. Treatment of disease due to Mycobacterium intracellulare // Rev. Infect. Dis. – 1981. – Vol. 3. – Р. 1052–1059.
  57. Diel R., Loddenkemper R., Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a meta-analysis //Chest. – 2010. – Vol. 137(4). – Р. 952–968.
  58. Diel R., Ringshausen F., Richter E., Welker L., Schmitz J., Nienhaus A.. Microbiological and Clinical Outcomes of Treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis // Chest. – 2017. – Vol. 152(1). – Р. 120–142.
  59. Dixmier A., Meynard J.L, Lalande V., Lebeau B., Chouaid C. Pulmonary infections with Mycobacterium xenopi in patients without HIV infection // Rev. Mal. Respir. – 2007. – Vol. 24. – Р. 299–304.
  60. Dutt A.K., Stead V.W. Long-term results of medical treatment in Mycobacterium intracellulare infection // Am. J. Med. – 1979. – Vol. 67. – Р. 449–453.
  61. Eisenberg E., Barza M. Azithromycin and clarithromycin // Curr. Clin. Top. Infect. Dis. Chest. – 1994. – Vol. 14. – Р. 52–79.
  62. Esteban J., Martin-de-Hijas N.Z., Garcia-Almeida D., Bodas-Sanchez A., Gadea I., Fernandez-Roblas R. Prevalence of erm methylase genes in clinical isolates of non- pigmented, rapidly growing mycobacteria // Clin. Microbiol. Infect. – 2009. – Vol. 15. – Р. 919–923.
  63. Evans A.J., Crisp A.J., Hubbard R.B., Colville A., Evans S.A., Johnston I.D.A. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis // Thorax. – 1996. – Vol. 51. – Р.1243–1247. Abstract.
  64. Falkinham J. Nontuberculous mycobacteria in the environment // Clin. Chest. Med.-2002. – Vol. 23. – P. 529–551.
  65. Falkinham J., Norton C., Le Chevallier M. Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare and other mycobacteria in drinking water distribution systems // Appl. Environ. Microbiol. – 2001. – Vol. 67. – P. 1225–1231.
  66. Falkinham J.O. Epidemiology of infection by nontuberculous mycobacteria // Clin. Microbiol. – 1996. – Rev. 9. – P. 177–215.
  67. Field S.K., Cowie R.L. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine // Chest. – 2003. – Vol. 124. – Р. 1482–1486.
  68. Francis P.B., Jay S.J., Johanson W.G. Jr. Course of un-treated Mycobacterium kansasii disease // Am. Rev. Respir. Dis. – 1975. – Vol. 111. – Р. 477–487.
  69. Furukawa B.S., Flume P.A. Nontuberculous Mycobacteria in Cystic Fibrosis // Semin. Respir. Crit. Care Med. – 2018. – Vol. 39(3). – Р. 383-391.
  70. Gail L. Woods M.D. Brown-Elliott B.A., Conville P.S., Desmond E.P., Hall G.S., Lin G., Pfyffer G.E., Ridderhof J.C., Siddiqi S.H., Wallace R.J. Jr, Warren N.G., Witebsky F.G. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. Approved Standard, M24A2E by Clinical and Laboratory Standards Institute. – 2011. – Report №: M24-A2ISBN-10: 1-56238-746-4.
  71. Gaviria J.M., Garcia P.J., Garrido S.M. et al. Nontuberculous mycobacterial infections in hematopoetic stem cell transplant recipients: characteristics of respiratory and catheter- related infections // Biol. Blood Morrow Thansplant. – 2000. – Vol. 6(4). – P. 361–369.
  72. Gelder C.M., Hart K.W., Williams O.M. et al. Vitamin D receptor gene polymorphisms and susceptibility to Mycobacterium malmoense pulmonary disease // J. Infect. Dis. – 2000. – Vol. 181. – Р. 2099–2102.
  73. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria // Chest. – 2008. – Vol. 133 (1). – P. 243 – 251.
  74. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised. – 2020.
  75. Good R.C. From the Center for Disease Control. Isolation of nontuberculous mycobacteria in the United States, 1979 // J. Infect. Dis. – 1980. – Vol. 142. – P. 779–783. Abstract.
  76. Griffith D., Aksamit T., Brown-Elliott B. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases // J. Resp. Crit. Care Med. – 2007. – Vol. 175, N. 4. – P. 367–416.
  77. Griffith D.E. The talking Mycobacterium abscessus blues // Clin. Infect. Dis. – 2011. – Vol. 52. – Р. 572–574.
  78. Griffith D.E., Brown B.A., Cegielski P., Murphy D.T., Wallace R.J. Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex // Clin. Infect. Dis. – 2000. – Vol. 302. – Р. 288–292.
  79. Griffith D.E., Brown B.A., Girard W.M., Griffith B.E., Couch L.A., Wallace R.J. Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease // Clin. Infect. Dis. – 2001. – Vol. 32. – Р. 1547–1553.
  80. Griffith D.E., Brown B.A., Girard W.M., Murphy D.T., Wallace R.J. Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus // Clin. Infect. Dis. – 1996. – Vol. 23. – Р. 983–989.
  81. Griffith D.E., Brown B.A., Murphy D.T., Girard W.M., Couch L.A., Wallace R.J. Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients // J. Infect. Dis. – 1998. – Vol. 178. – Р. 121–126.
  82. Griffith D.E., Brown-Elliott B.A., Langsjoen B., Zhang Y., Pan X., Girard W., Nelson K., Caccitolo J., Alvarez J., Shepherd S. et al. Clarithromycin-resistant Mycobacterium avium complex lung disease // Am. J. Respir. Crit. Care Med. – 2006. – Vol. 174. – Р. 928–934.
  83. Griffith D.E., Brown-Elliott B.A., Wallace R.J. Jr. Diagnosing nontuberculous mycobacterial lung disease. A process in evolution // Infect. Dis. Clin. North Am. – 2002. – Vol. 16. – Р. 235–249. Abstract.
  84. Griffith D.E., Brown-Elliott B.A., Wallace R.J. Jr. Thrice-weekly clarithromycin- containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study // Clin. Infect. Dis. – 2003. – Vol. 37. – Р. 1178–1182.
  85. Griffith D.E., Girard W.M., Wallace R.J. Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients // Am. Rev. Respir. Dis. – 1993. – Vol. 147. – Р. 1271–1278.
  86. Griffith D.E.. Nontuberculous mycobacterial lung disease // Curr. Opin. Infect. Dis. – 2010. – Vol. 23(2). – Р. 185–190.
  87. Hafeez I., Muers M.F., Murphy S.A. et al. Nontuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis // Thorax. – 2000. – Vol. 55(8). – P. 717–719.
  88. Hartman T.E., Swensen S.J., Williams D.E. Mycobacterium avium-intracellulare complex: evaluation with CT. Radiology. 1993;187:23-26. Abstract.
  89. Hatakeyama S., Ohama Y., Okazaki M., Nukui Y., Moriya K. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan // BMC Infect. Dis. – 2017. – Vol. 17(1). – Р. 197.
  90. Haworth C.S., Banks J., Capstick T., Fisher A.J., Gorsuch T., Laurenson I.F., Leitch A., Loebinger M.R., Milburn H.J., Nightingale M., Ormerod P., Shingadia D., Smith D., Whitehead N., Wilson R., Floto R.A. British Thoracic Society Guidelines for the Management of Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) // Thorax. – 2017. – Vol. 72. – Supp. ii1–ii64.
  91. Hayashi M., Takayanagi N., Kanauchi T., Miyahara Y., Yanagisawa T., Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease // Am. J. Respir. Crit. Care Med. – 2012. – Vol. 185(5). – Р. 575–583.
  92. Hazelton T.R., Newell J.D., Cook J.L. et al. CT finding in 14 patients with Mycobacterium chelonae pulmonary infection // Amer. J. Roentgenol. – 2000. – Vol. 175(2). – P. 413–416.
  93. Heidarieh P., Mirsaeidi M., Hashemzadeh M., Feizabadi M.M., Bostanabad S.Z., Nobar M.G., Hashemi Shahraki A. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran // Microb. Drug Resist. – 2016. – Vol. 22(2). – Р. 172–178.
  94. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. in Respir. Crit. Care Med. – 2004. – Vol. 25(3). – P. 283 – 295.
  95. Henriques B., Hoffner S.E., Petrini B. et al. Infection with Mycobacterium malmoense in Sweden: report of 221 cases // Clin. Infect. Dis. – 1994. – Vol. 18. – P. 596–600.
  96. Henry M.T., Inamdar L., O'Riordain D., Schweiger M., Watson J.P. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response // ERJ. – 2004. – Vol. 23(5). – P. 741–746.
  97. Ho N., Kurashima A., Morimoto К., Hoshino Y., Hasegawa N., Ato M., Mitarai S. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan // Emerg. Infect. Dis. – 2016. – Vol. 22(6). – Р. 1116–1117.
  98. Hoefsloot W., van Ingen J., Andrejak C., Angeby K., Bauriaud R., Bemer P., Beylis N., Boeree M.J., Cacho J., Chihota V., Chimara E., Churchyard G., Cias R., Daza R., Daley C.L., Dekhuijzen P.N., Domingo D., Drobniewski F., Esteban J., Fauville-Dufaux M., Folkvardsen D.B., Gibbons N., Gómez-Mampaso E., Gonzalez R., Hoffmann H., Hsueh P.R., Indra A., Jagielski T., Jamieson F., Jankovic M., Jong E., Keane J., Koh W.J., Lange B., Leao S., Macedo R., Mannsåker T., Marras T.K., Maugein J., Milburn H.J., Mlinkó T., Morcillo N., Morimoto K., Papaventsis D., Palenque E., Paez-Peña M., Piersimoni C., Polanová M., Rastogi N., Richter E., Ruiz-Serrano M.J., Silva A., da Silva M.P., Simsek H., van Soolingen D., Szabó N., Thomson R., Tórtola Fernandez T., Tortoli E., Totten S.E., Tyrrell G., Vasankari T., Villar M., Walkiewicz R., Winthrop K.L., Wagner D. Nontuberculous Mycobacteria Network European Trials Group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study // Eur. Respir. J. – 2013. – Vol. 42(6). – Р. 1604–1613.
  99. Hoefsloot W., van Ingen J., de Eange W.C., Dekhuijzen P.N., Boerce M.J., van Soolingen D. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands // Eur. Respir. J. – 2009. – Vol. 34. – P. 926–931.
  100. Hombach M., Somoskövi A., Hömke R., Ritter C., Böttger E.C. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST // Int. J. Med. Microbiol. – 2013. – Vol. 303(5). – Р.270–276.
  101. Horita Y., Maeda S., Kazumi Y., Doi N. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with beta-lactamase inhibitors // Antimicrob. Agents Chemother. – 2014. – Vol. 58(11). – Р. 7010–7014.
  102. Horsburgh C.R. Epidemiology of disease caused by nontuberculous mycobacteria // Semin. Respir. Infect. – 1996. – Vol. 11. – P. 244–251. Abstract.
  103. Horsburgh C.R. Jr, Mason U.G., Heifets L.B. III, Southwick K., Labrecque J., Iseman M.D. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing // Am. Rev. Respir. Dis. – 1987. – Vol. 135. – Р. 418–421.
  104. Huang C.W., Chen J.H., Hu S.T., Huang W.C., Lee Y.C., Huang C.C. et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan // Int. J. Antimicrob. Agents. – 2013. – Vol. 41(3). – Р. 218–223.
  105. Huang Y.C., Liu M.F., Shen G.H., Lin C.F., Kao C.C., Liu P.Y. et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing // J. Microbiol. Immunol. Infect. – 2010. – Vol. 43(5). – Р. 401–406.
  106. Ikeda M., Kobashi Y., Mouri K., Obase Y., Oka M. Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan // Eur. Respir. J. – 2012. – Vol. 40. -Suppl. 56. – 2708s.
  107. Iseman M.D., Marras T.K. The importance of nontuberculous mycobacterial lung disease // Am. J. Respir. Crit. Care Med. – 2008. – Vol. 178. – P. 999–1000.
  108. Jarvis W.R. The epidemiology of colonization, Infection Control and Nosocomial Colonization. – 1996. – Vol. 17. – Р. 47-52.
  109. Jenkins D.E., Bahar D., Chofnas I. Pulmonary disease due to atypical mycobacteria: current concepts. Transactions 19th Conference on Chemotherapy of Tuberculosis. – 1960. – Р. 224–231.
  110. Jenkins P.A., Banks J., Campbell I.A., Smith A.P. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol // Thorax J. - 1994. – Vol. 49. P. 442 – 445
  111. Jenkins P.A., Campbell I.A. Research Committee of The British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five-year follow-up of patients receiving standardised treatment // Respir. Med. – 2003. – Vol. 97. – Р. 439–444.
  112. Jenkins P.A., Campbell I.A., Banks J., Gelder C.M., Prescott R.J., Smith A.P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in the treatment of opportunist mycobacterial pulmonary diseases and an assessment of the value of immunotherapy with M. vaccae: a pragmatic, randomised trial by the British Thoracic Society // Thorax. – 2008. – Vol. 63. – Р. 627–634.
  113. Jeon K., Kim S.Y., Jeong B.H. et al. Severe vitamin D deficiency is associated with non- tuberculous mycobacterial lung disease: a case-control study // Respirology. – 2013. – Vol. 18. – Р. 983–988.
  114. Johnson M.M., Odell J.A. Nontuberculous mycobacterial pulmonary infections // J. Thorac. Dis. – 2014. – Vol. 6 (3). – Р. 210–219.
  115. Johnston J.C., Chiang L., Elwood K. Mycobacterium kansasii // Microbiol. Spectr. – 2017. – Vol. 5(1). doi: 10.1128/microbiolspec.TNMI7-0011-2016.
  116. Jones M.M., Winthrop K.L., Nelson S.D., Duvall S.L., Patterson O.V., Nechodom K.E., Findley K.E., Radonovich L.J. Jr, Samore M.H., Fennelly K.P. Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration // PLoS One. 2018 Jun 13;13(6):e0197976. doi: 10.1371/journal.pone.0197976. eCollection 2018.
  117. Jost K.C., Dunbar D.F., Barth S.S., Headley V.L., Elliott L.B. Identification of Mycobacterium tuberculosis and Mycobacterium avium complex directly from smear- positive sputum specimens and BACTEC 12B cultures by high-performance liquid chromatography with fluorescence detection and computer-driven pattern recognition models // J. Clin. Microbiol. – 1995. – Vol. 33. – Р. 1270–1277.
  118. Kanatani M.S., Guglielmo B.J. The new macrolides: azithromycin and clarithromycin // West J. Med. – 1994. Vol. 160. – Р. 31–37.
  119. Kartalija М., Ovrutsky A.R., Bryan C.L. et al. Patients with Nontuberculous Mycobacterial Lung Disease Exhibit Unique Body and Immune Phenotypes // Am. J. Respir. Crit. Care Med. – 2013. – Vol. 187(2). – Р. 197–205.
  120. Kasperbauer S.H., Daley C.L. Diagnosis and treatment of infections due to Mycobacterium avium complex // Semin. Respir. Crit. Care Med. – 2008. – Vol. 29(5). – Р. 569–576.
  121. Kasperbauer S.H., De Groote M.A. The treatment of rapidly growing mycobacterial infections // Clin. Chest Med. – 2015. – Vol. 36(1). – Р. 67-78.
  122. Kendall B., Winthrop K. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34 (1). – P. 87– 94.
  123. Khan K., Wang J., Marras T.K. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades // Am. J. Respir. Crit. Care Med. – 2007. – Vol. 176(3). – Р. 306–313.
  124. Kim E.Y., Chi S.Y., Oh I.J. et al. Treatment оutcome of сombination therapy including clarithromycin for Mycobacterium avium сomplex // Pulmonary Disease Korean J. Intern. Med. – 2011. – Vol. 26(1). – P. 54–59.
  125. Kim R., Greenberg D., Ehrmantraut M. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome // J. Respir. Crit. Care Med. – 2008. – Vol. 178 (10). – P. 1066–1074.
  126. Kim S.Y., Kim C.K., Bae I.K., Jeong S.H., Yim J.J., Jung J.Y. et al. The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea // Diagn. Microbiol. Infect. Dis. – 2015. – Vol. 81(2). – Р. 107–111.
  127. Kinjo T., Nei Y., Yamashiro S., Fujita J., Kishaba T. Causative species of nontuberculous mycobacterial lung disease and comparative investigation on clinical features of Mycobacterium abscessus complex disease: A retrospective analysis for two major hospitals in a subtropical region of Japan // PLoS One. – 2017. Oct 23;12(10): e0186826. Published online 2017 Oct 23. doi: 10.1371/journal.pone.0186826.
  128. Ko R.E., Moon S.M., Ahn S., Jhun B.W., Jeon K., Kwon O.J., Huh H.J., Ki C.S., Lee N.Y., Koh W.J. Changing Epidemiology of Nontuberculous Mycobacterial Lung Diseases in a Tertiary Referral Hospital in Korea between 2001 and 2015 // J. Korean Med. Sci. – 2018. – Vol. 33(8):e65.
  129. Kobashi Y., Matsushima T., Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease // Respir. Med. – 2007. – Р. 101. – Р. 130–138.
  130. Kobashi Y., Mouri K., Yagi S. et al. Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacterial disease // J. Tuberc. Lung Dis. – 2009. – Vol. 13 (11). – P. 1422–1426.
  131. Kobashi Y., Yoshida K., Miyashita N., Niki Y., Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug- sensitivity testing of Mycobacterium avium complex isolates // J. Infect. Chemother. – 2006. – Vol. 12. – Р. 195–202.
  132. Koh W., Kwon O., Lee K. Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases // J Korean Med Sci. – 2005. – Vol. 20 (6). – Р. 913–925.
  133. Koh W.J., Kim Y.H., Kwon O.J. Surgical Treatment of Pulmonary Diseases Due to Nontuberculous Mycobacteria // J Korean Med Sci. – 2008. – Vol. 23 (3). – Р. 397–401.
  134. Koh W.J., Kwon O.J., Jeon K. et al. Clinical significance of non-tuberculous mycobacteria isolated from respiratory specimens in Korea // Chest. – 2006. – Vol. 129. – P. 341–348.
  135. Lai C.C., Tan C.K., Chou C.H., Hsu H.L., Liao C.H., Huang Y.T., Yang P.C., Luh K.T., Hsueh P.R. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008 // Emerging infectious diseases. – 2010. – Vol. 16(2). – Р. 294–296.
  136. Lam P.K., Griffith D.E., Aksamit T.R., Ruoss S.J., Garay S.M., Daley C.L., Catanzaro A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease // Am. J. Respir. Crit. Care Med. – 2006. – Vol. 173. – Р. 1283–1289.
  137. Laube B.L., Janssens H.M., de Jongh F.H.C., Devadason S.G., Dhand R., Diot P., Everard M.L., Horvath I., Navalesi P., Voshaar T., Chrystyn H. What the pulmonary specialist should know about the new inhalation therapies // European Respiratory J. – 2011. – Vol. 37. – Р. 1308–1417.
  138. Leber A., Marras T.K. The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada // ERJ. – 2011. – Vol. 37(5). – P. 1158–1165.
  139. Levin M. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? // Lancet. – 1995. – Vol. 345. – P. 79–83.
  140. Leysen D., Haemers A., Pattyn S.R. Mycobacteria and the new quinolones // Antimicrob. Agents Chemother. – 1989. – Vol. 33. – P. 1–5.
  141. Li F., Li G.L., Pang H., Liu H.C., Xiao T., Li S.J., Luo Q., Jiang Y., Wang R.B., Wan K.L. Preliminary Study on Drug Susceptibility Profile and Resistance Mechanisms to Macrolides of Clinical Isolates of Non-tuberculous Mycobacteria from China // Biomed Environ Sci. – 2018. – Vol. 31(4). – Р. 290–299.
  142. Li W., Yazidi A., Pandya A.N., Hegde P., Tong W., Calado Nogueira de Moura V., North E.J., Sygusch J., Jackson M. MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections // Front. Microbiol. – 2018. Jul 10;9:1547. doi: 10.3389/fmicb.2018.01547. eCollection 2018
  143. Lim A.Y.H., Chotirmall S.H., Fok E.T.K., Verma A., De P.P., Goh S.K., Puah S.H., Goh D.E.L., Abisheganaden J.A. Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore // BMC Pulm. Med. – 2018. – Vol. 18(1):85. doi: 10.1186/s12890-018-0637-1.
  144. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party // Lancet. – 1981. Vol. 1. – Р. 681–686.
  145. Malouf M.A., Glanville A.R. The spectrum of mycobacterial infection after lung transplantation // Am. J. Respir. Crit. Care Med. – 1999. – Vol. 160. – P. 1611–1616.
  146. Mandler F. Mycobacteri e mycobacteriosi // Riv.Med.trentina. – 1990. – Vol. 28(1). – P. 11–20.
  147. Masson A.M., Prissick F.H. Cervical lymphadenitis in children caused by chromogenic Mycobacteria // Can. Med. Assoc. J. – 1956. – Vol. 75(10). – Р. 798–803.
  148. Maugein J., Dailloux M., Carbonnelle B., Vincent V., Grosset J. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease // Eur. Respir. J. – 2005. – Vol. 26(6). – Р. 1092–1096.
  149. Mazza-Stalder J., Jaton-Ogay K., Nicod L. Non tuberculous mycobacteria pulmonary disease: what's new? // Rev. Med. Suisse. – 2009. – Vol. 5(226). – Р. 2344–2346, 2348– 2350. Abstract.
  150. McCallum A.D., Watkin S.W., Faccenda J.F. Non-tuberculous mycobacterial infections in the Scottish Borders: identification, management and treatment outcomes--a retrospective review // The journal of the Royal College of Physicians of Edinburgh. – 2011. – Vol. 41(4). – Р. 294–303.
  151. McCracken D., Flanagan P., Hill D. et al. Cluster of cases of Mycobacterium chelonae bacteraemia // Europ. J. clin. Microbiol. Infect. Dis. – 2000. – Vol. 19(1). – P. 43–46.
  152. McGarvey J., Bermudez L.E. Pathogenesis of nontuberculous mycobacteria infections // Clin. Chest Med. – 2002. – Vol. 23(3). – Р. 569–583.
  153. McGrath E.E., Anderson P.B. The therapeutic approach to non-tuberculous mycobacterial infection of the lung // Department of Respiratory Medicine, Northern General Hospital, Sheffield, UK. – 2010. – Vol. 23 (5). – P. 389–396. Abstract.
  154. Meier T., Eulenbruch H.P., Wrighton-Smith P., Enders G., Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice // Eur. J. Clin. Microbial. Infect. Dis. – 2005. – Vol. 24(8). – P. 529– 536.
  155. Meissner G., Anz W. Sources of Mycobacterium avium-complex infection resulting in human disease // Am. Rev. Respir. Dis. – 1977. – Vol. 116. – P. 1057–1064. Abstract.
  156. Min J., Park J., Lee Y.J. et al. Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease // The Inter. J. of Tub. and Lung Disease. – 2015. – Vol. 19 (10). – P. 1239– 1245.
  157. Mirsaeidi M., Farshidpour M., Ebrahimi G., Aliberti S., Falkinham J.O. Management of Nontuberculous Mycobacterial Infection in The Elderly // Eur. J. Intern. Med. – 2014. – Vol. 25(4). – P. 356–363.
  158. Mirsaeidi M., Machado R.F., Garcia J.G.N., Schraufnagel D.E. Nontuberculous Mycobacterial Disease Mortality in the United States, 1999–2010; A Population-Based Comparative Study // PloS one. – 2014.
  159. Mitchell J.D., Bishop A., Cafaro A., Weyant M.J., Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease // Ann. Thorac. Surg. – 2008. – Vol. 85(6). – Р. 1887–1892.
  160. Moore E.H. Atypical mycobacterial infection in the lung: CT appearance // Radiology. – 1993. – Vol. 187. – P. 777–782.
  161. Moore J., Kruijshaar M.E., Ormerod L.P., Drobniewski F., Abubakar I. Increasing number of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. Health Protection, Agency Centre for Infections, Respiratory Diseases Department - Tuberculosis Section // BMC public health. – 2010. – Vol. 10. – Р. 612.
  162. Moran J.F., Alexander L.G., Stauh E.W., Young W.G., Sealy W.C. Long-term results of pulmonary resection for atypical mycobacterial disease // Am. Thorac. Surg. – 1983. Vol. 35. – Р. 597–604.
  163. Morrison D.A., Stovall J.R. Increased exercise capacity in hypoxemic patients after long- term oxygen therapy // Chest. – 1992. – Vol. 102. – Р. 542–550.
  164. Mortaz E., Moloudizargari M., Varahram M., Movassaghi M., Garssen J., Kazempour D.M, Mirsaeidi M, Adcock I.M. What Immunological Defects Predispose to Non- tuberculosis Mycobacterial Infections? // Iran J. Allergy Asthma Immunol. – 2018. – Vol. 17(2). – Р. 100–109.
  165. Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up patients receiving standardized treatment // Int. J. Tuberc. Lung Dis. – 2002. – Vol. 67. – Р. 628–634.
  166. Nakata N., Kai M., Makino M. Mutation analysis of mycobacterial rpoB genes and rifampin resistance using recombinant Mycobacterium smegmatis // Antimicrob. Agents Chemother. – 2012. – Vol. 56 (4). – Р. 2008–2013.
  167. Nash K.A., Zhang Y., Brown-Elliott B.A., Wallace R.J. Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum // J. Antimicrob. Chemother. – 2005. – Vol. 55(2). – Р. 170–177.
  168. Nelson K.G., Griffith D.E., Brown B.A., Wallace R.J. Jr. Results of operation in Mycobacterium avium-intracellulare lung disease // Ann. Thorac. Surg. – 1998. – Vol. 66. – Р. 325–330.
  169. Nie W., Duan H., Huang H., Lu Y., Chu N. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates // Biomed. Res. Int. – 2015. doi: 10.1155/2015/506598. Epub 2015 Jun 1.
  170. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial // Ann. Intern. Med. – 1980. – Vol. 93. – Р. 391–398.
  171. Nontuberculous Mycobacteriosis Control Committee of the Japanese Society for Tuberculosis; International Exchanging Committee of the Japanese Society for Tuberculosis. Guidelines for surgical therapy for pulmonary nontuberculous mycobacterial diseases // Kekkaku. – 2011. – Vol. 86. – Р. 41–42.
  172. Ogawa K., Sano C. Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation? // Kekkaku. – 2013. – Vol. 88(3). – Р. 355–371.
  173. Okamori S., Asakura T., Nishimura T., Tamizu E., Ishii M., Yoshida M., Fukano H., Hayashi Y., Fujita M., Hoshino Y., Betsuyaku T., Hasegawa N. Natural history of Mycobacterium fortuitum pulmonary infection presenting with migratory infiltrates: a case report with microbiological analysis // BMC Infect. Dis. – 2018. Vol. 18(1):1. doi: 10.1186/s12879-017-2892-9.
  174. Pai M., Riley L.W., Colford J.M. Interferon-gamma assay in the immunodiagnosis of tuberculosis: a systematic review // Lancet Infect. Dis. – 2004. – Vol. 4(12). – P. 761–776.
  175. Pang H., Li G., Zhao X., Liu H., Wan K., Yu P. Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China // Biomed. Res. Int. – 2015. doi: 10.1155/2015/419392. Epub 2015 Aug 13.
  176. Park S., Suh G.Y., Chung M.P., et al. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens // Respir. Med. – 2008. – Vol. 102. – P. 437–442.
  177. Patz E.F., Swensen S.J., Erasmus J. Pulmonary manifestations of nontuberculous mycobacteria // Radiol. Clin. North Am. – 1995. – Vol. 33. – P. 719–729.
  178. Peloquin C.A., Berning S.E., Nitta A.T., Simone P.M., Goble M., Huitt G.A., Iseman M.D., Cook J.L., Curan-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases // Clin. Infect. Dis. – 2004. – Vol. 38. – Р. 1538– 1544.
  179. Pelosi A., Smith D., Brammananth R., Topolska A., Billman-Jacobe H., Nagley P. et al. Identification of a novel gene product that promotes survival of Mycobacterium smegmatis in macrophages // PLoS One. 2012; 7 (2): e31788.
  180. Penny M.E., Cole R.B., Cray J. Two cases of Mycobacterium kansasii infection occurring in the same household // Tubercle. – 1982. – Vol. 63(2). – P. 129–131.
  181. Pezzia W., Raleigh J.W., Bailey M.C., Toth E.A., Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin // Rev. Infect. Dis. – 1981. – Vol. 3. – Р. 1035–1039.
  182. Pfyffer G.E., Ridderhof J.C., Siddiqi S.H., Wallace R.J. Jr, Warren N.G., Witebsky F.G., Woods G.L., Brown-Elliott B.A., Conville P.S., Desmond E.P., Hall G.S., Lin G. Susceptibility testing of Mycobacteria, Nocardiae and other Aerobic Actinomycetes; Approved standard –Second Edition. M24-A2. // Wayne (PA): Clinical and Laboratory Standards Institute. – 2011. – 76 p.
  183. Prevots D.R., Marras T.K. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review // Clin. Chest Med. 2015. – Vol. 36(1). – Р. 13 34.
  184. Prevots D.R., Shaw P.A., Strickland D., Jackson L.A., Raebel M.A., Blosky M.A., Montes de Oca R., Shea Y.R., Seitz A.E., Holland S.M., Olivier K.N. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems // Am. J. Respir. Crit. Care Med. – 2010. – Vol. 182(7). – Р. 970–976.
  185. Primack S.L., Logan P.M., Hartman T.E., Lee K.S., Muller N.L. Pulmonary tuberculosis and Mycobacterium avium- intracellulare: a comparison of CT findings // Radiology. – 1995. – Vol. 194. – P. 413–417.
  186. Primm T.P., Lucero C., Falkinham J.O. Impact on health of environmental mycobacteria // Clin. Microbiol. Rev. – 2004. – Vol.17. – Р. 98–106.
  187. Qvist T., Gilljam M., Jönsson B. et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia // Journal of cystic fibrosis. - 2015. – V. 14 (1). – P. 46–52.
  188. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.-F., Flaherty K.R., Lasky J.A., Lynch D.A., Ryu J.H., Swigris J.J., Wells A.U., Ancochea J., Bouros D., Carvalho C., Costabel U., Ebina M., Hansell D.M., Johkoh T., Kim D.S., King T.E.Jr., Kondoh Y., Myers J., Müller N.L., Nicholson A.G., Richeldi L., Selman M., Dudden R.F., Griss B.S., Protzko S.L., Schünemann H.J. An official ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence -based guidelines for diagnosis and management // Am. J. Respir. Crit. Care Med. – 2011. – Vol. 183(6). – Р. 788–824.
  189. Reich J., Johnson R. Mycobacterium avium complex pulmonary disease // Am. Rev. Respir. Dis. – 1991. – Vol. 143. – P. 1381 – 1385.
  190. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense and M. xenopi in HIV-negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol // Thorax. – 2001. – Vol. 56. – Р. 167–172.
  191. Ringshausen F.C., Wagner D., de Roux A., Diel R., Hohmann D., Hickstein L., Welte T., Rademacher J. Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009-2014 // Emerg. Infect. Dis. – 2016. – Vol. 22(6). – Р. 1102–1105.
  192. Rubin B.K., Henke M.O. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease // Chest. – 2004. – Vol. 125. – Р. 70S–78S.
  193. Sakatani M., Nakajima Y. Treatment of non-tuberculous pulmonary mycobacteriosis. National Hospital Organization Kinki-chuo Chest Medical Center, 1180, Nagasone-cho, Sakai-shi, Osaka 591-8555, Japan. – 2006. – Vol. 81(1). – Р. 35–50. Abstract.
  194. Salliot C., Desplaces N., Boisrenoult P. et al. Arthritis due to Mycobacterium xenopi: a retrospective study of 7 cases in France // Clin. Infect. Dis. – 2006. – Vol. 43. – Р. 987– 993.
  195. Satana D., Erkose-Genc G., Tamay Z., Uzun M., Guler N., Erturan Z. Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients // Annals of Clinical Microbiology and Antimicrobials. – 2014. – Р. 13–28.
  196. Sauret J., Hernandez-Flix S., Castro E., Hernandez L., Ausina V., Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy // Tuber. Lung Dis. – 1995. – Vol. 76. – Р. 104–108.
  197. Schoenfeld N., Haas W., Richter E., Bauer T., Boes L., Castell S., Hauer B., Magdorf K., Matthiessen W., Mauch H., Reuss A., Schenkel K., Ruesch-Gerdes S., Zabel P., Dalhoff K., Schaberg T., Loddenkemper R. Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses // Pneumologie. – 2016. – Vol. 70(4). – Р. 250–276.
  198. Seibert A.F., Bass J.B. Four drug therapy of pulmonary disease due to Mycobacterium avium complex. Annual Meeting of American Thoracic Society, May 14–17. Cincinnati, OH. // Am. Rev. Respir. Dis. – 1989. – Vol. 139(S). – A399. Abstract.
  199. Sexton P., Harrison A. Susceptibility to nontuberculous mycobacterial lung disease // Eur. Respir. J. – 2008. – Vol. 31 (6). – P. 1322–1333.
  200. Shah N.M., Davidson J.A., Anderson L.F. et al. Pulmonary Mycobacterium avium- intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012 // BMC Infect. Dis. – 2016. – Vol. 16. – Р. 195.
  201. Sherwood J.T., Mitchell J.D., Pomerantz M. Completion pneumonectomy for chronic mycobacterial disease // J. Thorac. Cardiovasc. Surg. – 2005. – Vol. 129(6). – Р. 1258– 1265.
  202. Shiraishi Y. Surgical treatment of nontuberculous mycobacterial lung disease // Gen. Thorac. Cardiovasc. Surg. – 2014. – Vol. 62(8). – Р. 475–480.
  203. Shiraishi Y., Fukushima K., Komatsu H., Kurashima A. Early pulmonary resection for localized Mycobacterium avium complex disease // Ann. Thorac. Surg. – 1998. – Vol. 66. – Р. 183–186.
  204. Shiraishi Y., Katsuragi N., Kita H., Hyogotani A., Saito M.H., Shimoda K. Adjuvant surgical treatment of nontuberculous mycobacterial lung disease // Ann. Thorac. Surg. – 2013. – Vol. 96. – Р. 287–291.
  205. Shiraishi Y., Nakajima Y., Katsuragi N., Kurai M., Takahashi N. Pneumonectomy for nontuberculous mycobacterial infections // Ann. Thorac. Surg. – 2004. – Vol. 78(2). – Р. 399–403.
  206. Shiraishi Y., Nakajima Y., Takasuna K., Hanaoka T., Katsuragi N., Konno H. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era // Eur. J. Cardiothorac. Surg. – 2002. – Vol. 21. – Р. 314–318.
  207. Shiva P.B., Tabarsi P., Marjani M., Masjedi M.R. Management and follow up of non- tuberculosis mycobacteria pulmonary infection in 55 infected cases in Iran // Eur. Respir. J. – 2011. – Vol. 38(55). – Р. 4378s.
  208. Shteinberg M., Stein N., Adir Y., Ken-Dror S., Shitrit D., Bendayan D., Fuks L., Saliba W. Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: a population survey // Eur. Respir. J. – 2018. – Vol. 51(5):1702469. doi: 10.1183/13993003.02469-2017.
  209. Skorberg K., Ruutu P., Tukiainen P. et al. Nontuberculous mycobacterial infection in HIV- negative patients receiving immunosuppressive therapy // Eur. J. Clin. Microbiol. Infect. Dis. – 1995. – Vol. 14. – P. 755–763.
  210. Smith M.J., Citron K.M. Clinical review of pulmonary disease caused by Mycobacterium xenopi // Thorax. – 1983. – Vol. 38(5). – Р. 373–377.
  211. Somoskovi A., Mester J., Hale Y.M., Parsons L.M., Salfinger M. Laboratory diagnosis of nontuberculous mycobacteria // Clin. Chest Med. – 2002. – Vol. 23. – Р. 585–597.
  212. Somoskovi A., Salfinger M. Nontuberculous mycobacteria in respiratory infections: advances in diagnosis and identification // Clin. Lab. Med. – 2014. – Vol. 34(2). – Р. 271– 295.
  213. Song Y., Zhang L., Yang H., Liu G., Huang H., Wu J., Chen J. Nontuberculous mycobacterium infection in renal transplant recipients: a systematic review // Infect. Dis. (Lond). – 2018. – Vol. 50(6). – Р. 409–416.
  214. Sood G., Parrish N. Outbreaks of nontuberculous mycobacteria // Current Opinion in Infectious Diseases. – 2017. – Vol. 30(4). – Р. 404–409.
  215. Springer B., Stockman L., Teschner K., Roberts G.D., Böttger E.C. Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods // J. Clin. Microbiol. – 1996. – Vol. 34. – Р. 29.
  216. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. – Thorax. – 2000. – Vol. 55. – Р. 210–218.
  217. Sugihara E., Hirota N., Niizeki T. et al. Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MC) infection // J. Infect. Chemother. – 2003. – Vol. 9. – Р. 328–332. Abstract.
  218. Suzuki K., Kurashima A., Tatsuno K., Kadota J.I. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare lung disease from post-marketing surveillance // Respir. Investig. – 2018. – Vol. 56(1). – Р. 87–93.
  219. Tanaka E., Kimoto T., Tsuyuguchi K., Watanabe I., Matsumoto H., Niimi A., Suzuki K., Murayama T., Amitani R., Kuze F. Effect of clarithromycin regimen for Mycobacteriuim avium complex pulmonary disease // Am. J. Respir. Crit. Care Med. – 1999. – Vol. 160. – Р. 866–872.
  220. Thomas P., Liu F., Weiser W. Characteristics of Mycobacterium xenopi disease // Bull Int. Union Tuberc. Lung Dis. – 1988. – Vol. 63 (3). – Р. 12–13.
  221. Thomson R.M. Changing epidemiology of pulmonary nontuberculous mycobacteria infections // Emerg. Infect. Dis. – 2010. – Vol. 16(10). – Р. 1576–1583.
  222. Timpe A., Runyon E.H. The relationship of «atypical» acid-fast bacteria to human disease // J. Lab. Clin. Med. – 1954. – Vol. 44. – P. 202–209.
  223. Tortoli E. Clinical manifestation of nontuberculous mycobacterial infections // Clin. Microbiol. Infect. – 2009. – Vol. 15 (10). – P. 906–910.
  224. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s // Clin. Microbiol. Rev. – 2003. – Vol. 16. – P. 319–354. Abstract.
  225. Tsuji T., Tanaka E., Hashimoto S., Hajiro T., Taguchi Y. Prevalence of nontuberculous mycobacteria in diffuse panbronchiolitis // Eur. Respir. J. – 2012. – Vol. 40(56). – Р. 1730s.
  226. van Ingen J. Treatment of pulmonary disease caused by non-tuberculous mycobacteria // Lancet Respir. Med. – 2015. – Vol. 3(3). – Р. 179–180.
  227. van Ingen J., Bendien S.A., de Lange W.C. et al. Clinical relevance of nontuberculous mycobacteria isolated in the Nijmegen-Arngem region, The Netherlands // Thorax. – 2009. – Vol. 64. – P. 502–506.
  228. van Ingen J., Boeree M.J., de Lange W.C., de Haas P.E., Dekhuijzen P.N., van Soolingen D. Clinical relevance of Mycobacterium szulgai in The Netherlands // Clin. Infect. Dis. – 2008. – Vol. 46. – P. 1200–1205.
  229. van Ingen J., de Zwaan R., Dekhuijzen R.P., Boeree M.J., van Soolingen D. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients // J. Infect. – 2009. – Vol. 59. – P. 324–331.
  230. van Ingen J., Egelund E.F., Levin A., Totten S.E., Boeree M.J., Mouton J.W., Aarnoutse R.E., Heifets L.B., Peloquin C.A., Daley C.L. The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment // Am. J. Respir. Crit. Care Med. – 2012. – Vol. 186(6). – Р. 559– 565.
  231. van Ingen J., Ferro B.E., Hoefsloot W. et al: Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence // Expert Rev. Anti. Infect. Ther. – 2013. – Vol. 11. – Р. 1065–1077.
  232. Varadi R.G., Marras T. K. Pulmonary Mycobacterium xenopi infection in non-HIV- infected patients: a systematic review // Int. J. Tuberc. Lung Dis. – 2009. – Vol. 13(10). – Р. 1210–1218.
  233. Varghese B., Enani M., Shoukri M., Johani S., Al-Ghafli H., Al-Thawadi S., Al-Hajoj S. The first Saudi Arabian national inventory study revealed the upcoming challenges of highly diverse non-tuberculous mycobacterial diseases // PLoS Negl Trop Dis. 2018 May 25;12(5):e0006515. doi: 10.1371/journal.pntd.0006515. eCollection 2018 May.
  234. Varghese В., Enani M.A., Al-Тhawadi S., Johani S., Fernandez G.M., Al-Ghafli H., Al- Hajoj S. Mycobacterium riyadhense in Saudi Arabia // Emerg. Infect. Dis. – 2017. – Vol. 23(10). – Р. 1732–1734.
  235. Venugopal D., Kumar S., Isa M., Bose M. Drug resistance profile of human Mycobacterium avium complex strains from India // Indian J. Med. Microbiol. – 2007. – Vol 25(2). – Р. 115–120.
  236. Viviani L., Harrison M.J., Zolin A., Haworth C.S., Floto R.A. Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF) // J. Cyst. Fibros. – 2016. – V. 15 (5). – P. 619–623.
  237. Von Reyn C., Horsburgh C., Olivier K. et al. Skin test reaction to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States // Int. J. Tuberc. Lung. Dis. – 2001. – Vol. 5. – P. 1122–1128.
  238. Von Rhein C.F., Arbeit R.D., Horsburgh R., Ristola M.A., Waddell R.D., Tvaroha S.M. et al. Sources of disseminated Mycobacterium avium infection in AIDS // J. Infect. – 2002. – Vol. 44. – Р. 166–170.
  239. Von Rhein C.F., Waddell R.D., Eaton T. et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya // J. Clin. Microbiol. – 1993. – Vol. 12. – P. 3227–3230.
  240. Wallace R.J. Jr., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T., Onyi G.O., Steingrube V.A., Mazurek G.H. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease // Am. J. Respir. Crit. Care Med. – 1994. – Vol. 149. – Р. 1335–1341.
  241. Wallace R.J. Jr., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients // Am. J. Respir. Crit. Care Med. – 1996. – Vol. 153. – Р. 1766–1772.
  242. Wallace R.J. Jr., Brown B.A., Onyi G. Susceptibilities of Mycobacterium fortuitum biovar and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid // Antimicrob. Agents Chemother. – 1991. – Vol. 35. – P. 773–775.
  243. Wallace R.J. Jr., Brown B.A., Onyi G.O. Skin, soft tissue, and bone infections due to Mycobacterium chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin // J. Infect. Dis. – 1992. – Vol. 166. – Р. 405–412.
  244. Wallace R.J. Jr., Brown-Elliott B.A., Crist C.J., Mann L., Wilson R.W. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria // Antimicrob. Agents Chemother. – 2002. – Vol. 46(10). – Р. 3164–3167.
  245. Wallace R.J. Jr., Cook J.L., Glassroth J., Griffith D.E., Olivier K.N., Gordin F. American Thoracic Society statement: diagnosis and treatment of disease caused by nontuberculous mycobacteria // Am. J. Respir. Crit. Care Med. – 1997. – Vol. 156. – Р. S1–S25.
  246. Wallace R.J. Jr., Dukart G., Brown-Elliott B.A., Griffith D.E., Scerpella E.G., Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections // J. Antimicrob. Chemother. – 2014. – Vol. 69(7). – Р. 1945–1953.
  247. Wallace R.J. Jr., Dunbar D., Brown B.A., Onyi G., Dunlap R., Ahn C.H., Murphy D.T. Rifampin-resistant Mycobacterium kansasii // Clin. Infect. Dis. – 1994. – Vol. 18. – P. 736– 743.
  248. Wallace R.J. Jr., Swenson J.M., Silcox V.A., Bullen M.G. Treatment of non-pulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities // J. Infect. Dis. – 1985. – Vol. 152. – P. 500–514.
  249. Wallace R.J. Jr., Tanner D., Brennan P.J., Brown B.A. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae // Ann. Intern. Med. – 1993. – Vol. 119. – Р. 482–486.
  250. Wallace R.J. Jr., Zhang Y., Brown-Elliott B.A., Yakrus M.A., Wilson R.W., Mann L. et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis // J. Infect. Dis. – 2002. – Vol. 186. – Р. 266–273.
  251. Wallace R.J., Brown B.A., Onyi G.O. Skin, soft tissue, and bone infections due to Mycobacterium chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin // J. Infect. Dis. – 1982. – Vol. 166. – Р. 405–412.
  252. Wassilew N., Hoffmann H., Andrejak C., Lange C. Pulmonary Disease Caused by Non- Tuberculous Mycobacteria // Respiration. – 2016. – Vol. 91(5). – Р. 386–402.
  253. Winthrop K. Pulmonary disease due to nontuberculous mycobacteria: an epidemiologists view // Future Microbiol. – 2010. – Vol. 5(3). – P. 343–345.
  254. Wolinsky E. Mycobacterial diseases other than tuberculosis // Clin. Infect. Dis. – 1992. – Vol. 15. – P. 1–12.
  255. Wolinsky E. Nontuberculous mycobacteria and associated diseases // Am. Rev. Respir. Dis. – 1979. – Vol. 119(1). – Р. 107–159.
  256. Wu J., Zhang Y., Li J., Lin S., Wang L., Jiang Y., Pan Q., Shen X. Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study // PLoS One. – 2014. Oct 16;9(10):e109736. doi: 10.1371/journal.pone.0109736. eCollection 2014.
  257. Wu T.S., Leu H.S., Chiu C.H., Lee M.H., Chiang P.C., Wu T.L., Chia J.H., Su L.H., Kuo A.J., Lai H.C. Clinical manifestations, antibiotic susceptibility and molecular analysis of Mycobacterium kansasii isolates from a university hospital in Taiwan // J. Antimicrob. Chemother. – 2009. – Vol. 64(3). – Р. 511–514.
  258. Wu U.I., Holland S.M. A genetic perspective on granulomatous diseases with an emphasis on mycobacterial infections // Semin. Immunopathol. – 2016. – Vol. 38(2). – Р. 199–212.
  259. Yamada K., Sugiyama T., Yasuda A., Seki Y., Hasegawa M., Hayashi Y. et al. A study of relapse/recurrence cases after surgical treatment for patients with pulmonary nontuberculous mycobacteriosis [in Japanese] // Kekkaku. – 2013. – Vol. 88. – Р. 469– 475.
  260. Yang S.C., Hsueh P.R., Lai H.C., Teng L.J., Huang L.M., Chen J.M., Wang S.K., Shie D.C., Ho S.W., Luh K.T. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan // Antimicrob. Agents Chemother. – 2003. – Vol. - 47(6). – Р. 1958–1962.
  261. Ye H., Zeng J., Qin W., Yang Z., Yang L., Wu Z., Du G. A totally implantable venous access port associated with bloodstream infection caused by Mycobacterium fortuitum: A case report. Medicine (Baltimore) // 2018. – Vol. 97(29). – Р. e11493.
  262. Yeager H. Jr., Raleigh J.W. Pulmonary disease due to Mycobacterium intracellulare // Am. Rev. Respir. Dis. – 1973. – Vol. 108. – Р. 547–552.
  263. Yoon H.J., Choi H.Y., Ki M. Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea // BMC Infect. Dis. 2017. – Vol. 17(1). – Р. 432.
  264. Young L.S., Wiviott L., Wu M. et al. Azithromycin for treatment of Mycobacterium avium- intracellulare complex infection in patients with AIDS // Lancet. – 1991. – Vol. 338. – P. 1107–1109.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*